Key result
Low molecular weight heparin prophylaxis after total knee arthroplasty reduces the prevalence of deep vein thrombosis from up to 84% to 30.6%.
Why the study?
Does low molecular weight heparin prophylaxis prevent venous thromboembolism in patients undergoing total knee arthroplasty?
Does low molecular weight heparin prophylaxis prevent venous thromboembolism in patients undergoing total knee arthroplasty?
Low molecular weight heparin provides safe and effective prophylaxis against venous thromboembolism following total knee arthroplasty, despite a residual venographic deep vein thrombosis rate of 30.6%.
Answers are grounded in this paper and cite their sources.
May support LMWH prophylaxis after TKA; leaves open need for randomized trials on VTE prevention.
Venous thrombosis continues to be a major risk after total knee arthroplasty. Without prophylaxis, the prevalence of deep vein thrombosis is as high as 84%, with proximal occurrence as high as 20%. Of more concern is the occurrence of pulmonary embolism as high as 7%, with fatal pulmonary embolism as high as 0.7%. This high prevalence mandates that prophylaxis for thromboembolic disease be used for patients undergoing total knee arthroplasty. Low molecular weight heparin has been studied extensively and is safe and effective prophylaxis after total knee arthroplasty. Low molecular weight heparins have a predictable dose response, offer high bioavailability at low doses, and produce linear pharmacokinetics. It has a half-life of approximately 4.5 hours providing effective dosing every 12 to 24 hours with rapid antithrombotic action. Routine pharmacologic prophylaxis with low molecular weight heparin seems to be effective in decreasing the occurrence of venous thromboembolism. However, venographic prevalence of deep vein thrombosis among patients undergoing total knee arthroplasty and receiving prophylaxis remains substantial at 30.6%. Prophylaxis with low molecular weight heparin beyond hospitalization may be indicated with decreased hospital stays, although studies have not been convincing that extended outpatient prophylaxis for more then 7 to 10 days is necessary.
No takes yet. Share an insight, caveat, or question.
Clifford W. Colwell (2001) conducted a review in Total knee arthroplasty. Low molecular weight heparin vs. No prophylaxis was evaluated on Deep vein thrombosis. Low molecular weight heparin prophylaxis after total knee arthroplasty reduces the prevalence of deep vein thrombosis from up to 84% to 30.6%.
Synapse has enriched 10 related papers. Consider them for comparative context: